Compare VMET & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VMET | DNA |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 982.2M | 835.7M |
| IPO Year | 2025 | 2020 |
| Metric | VMET | DNA |
|---|---|---|
| Price | $9.14 | $11.35 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 3 |
| Target Price | ★ $14.31 | $8.00 |
| AVG Volume (30 Days) | 232.1K | ★ 2.6M |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | $155.17 | N/A |
| Revenue Next Year | $37.11 | $13.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.87 | $5.37 |
| 52 Week High | $13.81 | $18.22 |
| Indicator | VMET | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 51.79 |
| Support Level | $9.10 | $6.75 |
| Resistance Level | $9.87 | $13.97 |
| Average True Range (ATR) | 0.35 | 1.26 |
| MACD | 0.11 | -0.11 |
| Stochastic Oscillator | 83.67 | 41.15 |
Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.